Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis
NCT ID: NCT00445874
Last Updated: 2009-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
120 participants
INTERVENTIONAL
2007-02-28
2007-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis
NCT00432757
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
NCT05591755
Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis
NCT00241319
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
NCT00244543
Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis
NCT00133627
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ketotifen with a Contact Lens (no generic name)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Successful soft contact lens wearer who has frequently worn contact lenses for at least one month or more
Exclusion Criteria
* Clinically significant blepharitis
* Follicular conjunctivitis
* Pterygium
* Narrow angle glaucoma
* Dry eye dyndrome
* Ocular surgery within past 6 months
* Pregnancy or lactation
8 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vistakon Pharmaceuticals
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brian Pall, OD, MS, FAAO
Role: STUDY_DIRECTOR
Vistakon Pharmaceutical
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix, Arizona, United States
Phoenix, Arizona, United States
Irvine, California, United States
North Andover, Massachusetts, United States
Cincinnati, Ohio, United States
Fairfield, Ohio, United States
Mason, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06-003-23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.